Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014